Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 10/20 | 0.49 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.41 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.41 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.41 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.41 |
| ▸ | HK1 | P19367 | 2/20 | 0.41 |
| ▸ | HK2 | P52789 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13077060 | 0.87 | SELE (0.54) | SELELGALS3 | |
| SCHEMBL13077057 | 0.85 | SELE (0.57) | SELELGALS9LGALS1LGALS3LGALS7; LGALS7B | |
| SCHEMBL13077746 | 0.83 | SELE (0.50) | SELE | |
| SCHEMBL12310109 | 0.79 | SELE (0.54) | SELELGALS9LGALS1LGALS3LGALS7; LGALS7B | |
| SCHEMBL12631208 | 0.79 | SELE (0.53) | SELELGALS9LGALS1LGALS3LGALS7; LGALS7B | |
| SCHEMBL12239769 | 0.74 | SELE (0.59) | SELELGALS9LGALS1LGALS3LGALS7; LGALS7B | |
| SCHEMBL14823281 | 0.74 | SELE (0.55) | SELELGALS9LGALS1LGALS3LGALS7; LGALS7B | |
| SCHEMBL8514368 | 0.74 | SELE (0.55) | SELELGALS9LGALS1LGALS3LGALS7; LGALS7B | |
| SCHEMBL8514365 | 0.74 | SELE (0.55) | SELELGALS9LGALS1LGALS3LGALS7; LGALS7B | |
| SCHEMBL8515435 | 0.74 | SELE (0.55) | SELELGALS9LGALS1LGALS3LGALS7; LGALS7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100279965-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS | GLYCOMIMETICS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279965-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS | CXCL12, CXCR4, SELE | SELE 3/4885CA1 3439/4885CA2 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.